Core Viewpoint - The announcement indicates that Weikang Pharmaceutical is collaborating with Yingkerui (Zhuhai Jinwan) Pharmaceutical Co., Ltd. to initiate a Phase III clinical trial for Huangjia Soft Liver Granules, aimed at evaluating its efficacy and safety in treating chronic hepatitis B-related liver fibrosis [1] Group 1 - Weikang Pharmaceutical and Yingkerui are jointly applying for a clinical trial [1] - The leading unit for the trial is Shanghai University of Traditional Chinese Medicine Affiliated Shuguang Hospital, with participation from 19 clinical trial centers including Anhui Medical University First Affiliated Hospital and Chongqing University Affiliated Three Gorges Hospital [1] - The trial is designed as a randomized, double-blind, multi-center, placebo-controlled study [1] Group 2 - The company will actively promote the Phase III clinical trial of Huangjia Soft Liver Granules in accordance with national requirements and expert recommendations following the project kickoff meeting [1]
维康药业：黄甲软肝颗粒启动临床Ⅲ期试验